Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SILO

Silo Pharma (SILO)

Silo Pharma Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SILO
DateTimeSourceHeadlineSymbolCompany
06/13/20245:08PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SILOSilo Pharma Inc
06/13/20241:19PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SILOSilo Pharma Inc
06/11/20244:00PMEdgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:SILOSilo Pharma Inc
06/07/20248:18AMGlobeNewswire Inc.Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for FibromyalgiaNASDAQ:SILOSilo Pharma Inc
06/06/20244:52PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SILOSilo Pharma Inc
06/06/20244:50PMGlobeNewswire Inc.Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesNASDAQ:SILOSilo Pharma Inc
06/06/20246:07AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SILOSilo Pharma Inc
06/05/20248:00AMGlobeNewswire Inc.Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesNASDAQ:SILOSilo Pharma Inc
06/04/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SILOSilo Pharma Inc
06/04/20248:41AMGlobeNewswire Inc.Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and AnxietyNASDAQ:SILOSilo Pharma Inc
05/21/20248:45AMGlobeNewswire Inc.Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse PreventionNASDAQ:SILOSilo Pharma Inc
05/14/20248:45AMGlobeNewswire Inc.Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in KetamineNASDAQ:SILOSilo Pharma Inc
05/13/20244:05PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SILOSilo Pharma Inc
04/23/20248:15AMGlobeNewswire Inc.Silo Pharma Announces Positive Results for Intranasal PTSD TreatmentNASDAQ:SILOSilo Pharma Inc
04/10/20248:11AMGlobeNewswire Inc.Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease TherapeuticNASDAQ:SILOSilo Pharma Inc
03/20/20248:30AMGlobeNewswire Inc.Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety TherapeuticNASDAQ:SILOSilo Pharma Inc
03/18/20247:15AMGlobeNewswire Inc.Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic PainNASDAQ:SILOSilo Pharma Inc
02/28/20248:25AMGlobeNewswire Inc.Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSDNASDAQ:SILOSilo Pharma Inc
02/14/20248:45AMGlobeNewswire Inc.Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug DeliveryNASDAQ:SILOSilo Pharma Inc
02/01/20241:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SILOSilo Pharma Inc
02/01/202410:00AMGlobeNewswire Inc.Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and NeurologyNASDAQ:SILOSilo Pharma Inc
01/31/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SILOSilo Pharma Inc
01/25/20245:29PMEdgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:SILOSilo Pharma Inc
01/25/20245:27PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SILOSilo Pharma Inc
01/24/20248:55AMGlobeNewswire Inc.Silo Pharma Announces Positive Results in Alzheimer’s Disease StudyNASDAQ:SILOSilo Pharma Inc
01/23/20245:01PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SILOSilo Pharma Inc
01/11/202412:15PMEdgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:SILOSilo Pharma Inc
01/09/20244:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SILOSilo Pharma Inc
01/04/20248:55AMGlobeNewswire Inc.Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSDNASDAQ:SILOSilo Pharma Inc
12/28/20238:25AMGlobeNewswire Inc.Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for FibromyalgiaNASDAQ:SILOSilo Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:SILO